Alzheimer’s research focuses on links to sleep and other behaviours
Alzheimer’s research is increasingly focused on links to sleep and other behaviors according to a new report released by Elsevier. To coincide with World Alzheimer’s...
Novartis Luxturna®▼ recommended on NHS for rare inherited eye disorder
Novartis Luxturna®, a novel gene therapy treatment for rare inherited eye disorder, has been recommended by NICE for use on the NHS. The draft highly-specialised...
Sandoz announce global deal to comercialise natalizumab
Sandoz, a Novartis division and a global leader in biosimilars, has entered into a global commercialisation agreement with Polpharma Biologics for a proposed natalizumab...
AstraZeneca’s Brilinta reduces CV events risk in Phase III trial
AstraZeneca has announced detailed results from the positive Phase III THEMIS trial which showed Brilinta (ticagrelor) plus aspirin reduced the relative risk for the...
New antibiotic molecule being developed in fight against antibiotic-resistant bacteria
Northern Antibiotics is working on a new antibiotic molecule that it hopes will become a weapon against antibiotic bacteria. Each year, around 60,000 deaths are...
New research could boost innovative cancer treatments
Removing cancer's protective barrier could boost effectiveness of innovative cancer treatments like immunotherapy, according to early research part-funded by Cancer Research UK.
In the study,...
MSD and Francis Crick Institute launch new motor neurone disease collaboration
Scientists at MSD and the Francis Crick Institute have started a unique new motor neurone disease collaboration to understand the causes and identify potential...
NICE to work with GW Pharma on cannabidiol evaluation
NICE has announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of...
NHS Spine marks five-year anniversary
NHS Spine is marking five years since it was brought in house by NHS Digital and run as an open source service for the...
Positive phase III study results for injectable HIV-treatment regimen
ViiV Healthcare has announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen (2DR) of ViiV...
Latest articles
Drug firms admit to colluding to keep up prices of antidepressants
Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...
Licensing status of Avastin updated by MHRA
The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners 2019
Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Licensing status of Avastin updated by MHRA
The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners 2019
Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...
Poor diabetes control costs the NHS £3bn in avoidable treatment
New research finds that poor diabetes control costs the NHS £3bn in potentially avoidable hospital treatment in England. The findings, being presented at this year’s...
Drug firms admit to colluding to keep up prices of antidepressants
Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...